NCT06858332

Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 2,382 (estimated)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

This study has the purpose to answer how the Lipoprotein(a) (Lp(a)) level is distributed among Atherosclerotic cardiovascular disease (ASCVD) patients in Russia, and what is the connection between elevated levels of this parameter and the cardiovascular disease (CVD) risk.

Detailed description

This study will consist of several phases (consecutive stages): Phase I: a cross-sectional study of Lp(a) level with ASCVD patients Phase II: * A non-interventional, prospective, cohort study with the phase I patients * A cross-sectional study of Lp(a) levels with relatives of phase I patients * A non-interventional, prospective, cohort study with patients' relatives

Conditions

• Atherosclerotic Cardiovascular Disease

Interventions

Type	Name	Description
DRUG	Atorvastatin	3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins)
DRUG	Simvastatin	3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins)
DRUG	Rozuvastatin	3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins)
DRUG	Ezetimibe	Ezetimibe
DRUG	Niacin	Niacin
DRUG	Ciprofibrate	Fibrates
DRUG	Fenofibrate	Fibrates
DRUG	Bezafibrate	Fibrates
DRUG	Evolocumab	PCSK9 inhibitor
DRUG	Alirocumab	PCSK9 inhibitor
DRUG	Inclisiran	Small interfering RNA

Timeline

• Start date: 2025-04-15
• Primary completion: 2027-09-30
• Completion: 2027-09-30
• First posted: 2025-03-05
• Last updated: 2025-08-03

Locations

20 sites across 1 country: Russia